Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Other Accumulated Expenses (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Other Accumulated Expenses for 6 consecutive years, with $46.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 128.6% to $46.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $46.9 million, a 128.6% increase, with the full-year FY2025 number at $46.9 million, up 128.6% from a year prior.
  • Other Accumulated Expenses was $46.9 million for Q4 2025 at GeneDx Holdings, up from $32.9 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $81.6 million in Q2 2022 to a low of $727000.0 in Q3 2024.
  • A 5-year average of $24.5 million and a median of $23.2 million in 2021 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: crashed 98.77% in 2023, then soared 4419.67% in 2025.
  • GeneDx Holdings' Other Accumulated Expenses stood at $33.4 million in 2021, then tumbled by 89.24% to $3.6 million in 2022, then plummeted by 61.62% to $1.4 million in 2023, then soared by 1386.44% to $20.5 million in 2024, then skyrocketed by 128.6% to $46.9 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Other Accumulated Expenses are $46.9 million (Q4 2025), $32.9 million (Q3 2025), and $19.1 million (Q2 2025).